The anti-intellectual effects of intellectual property.
Intellectual property considerations decrease research productivity in subtle and unanticipated ways. Chemical probe exchange between Pharma and academia is hindered by academic IP interests. These are perceived as a subtle nuisance by the academic researcher. Novel ligands for oral targets are historically few and numbers of economically attractive oral drug targets are limited. Economically speculative targets lie in the academic domain but the medicinal chemistry to explore these in a drug discovery sense lies in Pharma and cooperation between the two is hindered by very different academic and Pharma views on chemical quality. Tools and probes for academic target validation can accommodate looser chemical quality criteria as opposed to the very strict chemical quality criteria required in Pharma drug discovery.
Lipinski
Christopher A
CA
Scientific Advisor, Melior Discovery, 10 Connshire Drive, Waterford, CT 06385-4122, USA. clipinski@meliordiscovery.com
D000047:Academies and Institutes; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000191:economics*; D004345:Drug Industry; D018973:Intellectual Property